Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States

BACKGROUND: Immune checkpoint inhibitors targeting the programmed cell death protein‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) axis (collectively referred to as PD[L]1i) have demonstrated clinical benefits in non‐small cell lung cancer (NSCLC) patients. The purpose of this United States‐based r...

Descripción completa

Detalles Bibliográficos
Autores principales: Veluswamy, Rajwanth, Hirsch, Fred R., Taioli, Emanuela, Wisnivesky, Juan, Strauss, Ross, Harrough, Douglas, Tang, Boxiong, Barnes, Gisoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678105/
https://www.ncbi.nlm.nih.gov/pubmed/35499294
http://dx.doi.org/10.1002/cam4.4785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678105/
https://www.ncbi.nlm.nih.gov/pubmed/35499294
http://dx.doi.org/10.1002/cam4.4785

Ejemplares similares